PTC Therapeutics Stock Price | PTCT Stock Quote, News, and History
Michael Hansen 
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Total Analysts: 51
Buy Ratings: 17 Neutral Ratings: 27 Sell Ratings: 7
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 17.00 Median: 48.59 Highest: 76.00
- All
- Buy
- Hold
- Sell
| 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|
| Revenue | 655 | 649 | 707 | 787 |
| Dividend | 0.00 | 0.00 | 0.00 | - |
| Dividend Yield (in %) | - | - | - | - |
| EPS | -5.58 | -4.29 | -2.78 | -2.29 |
| P/E Ratio | -4.90 | -6.37 | -9.83 | -11.95 |
| EBIT | -285 | -206 | -91 | -54 |
| EBITDA | 26 | -15 | 60 | - |
| Net Profit | -404 | -329 | -231 | -192 |
| Net Profit Adjusted | -223 | -151 | - | - |
| Pre-Tax Profit | -395 | -319 | -219 | -186 |
| Net Profit (Adjusted) | -269 | -97 | 144 | 434 |
| EPS (Non-GAAP) ex. SOE | -4.62 | -3.37 | 0.02 | 1.78 |
| EPS (GAAP) | -5.58 | -4.29 | -2.78 | -2.29 |
| Gross Income | 559 | 502 | 517 | 437 |
| Cash Flow from Investing | -29 | -29 | -27 | -27 |
| Cash Flow from Operations | -257 | -243 | -317 | -253 |
| Cash Flow from Financing | 67 | 100 | -44 | 150 |
| Cash Flow per Share | -2.89 | -1.93 | - | - |
| Free Cash Flow | -207 | -79 | - | - |
| Free Cash Flow per Share | - | - | - | - |
| Book Value per Share | -10.05 | -9.53 | - | - |
| Net Debt | -426 | -313 | -111 | -189 |
| Research & Development Exp. | 527 | 502 | 480 | 486 |
| Capital Expenditure | 29 | 29 | 27 | 27 |
| Selling, General & Admin. Exp. | 254 | 257 | 267 | 271 |
| Shareholder’s Equity | -729 | -881 | 84 | 645 |
| Total Assets | 1,437 | 1,593 | 2,138 | 2,353 |
| Previous Quarter ending 12/31/23 | Current Quarter ending 03/31/24 | Next Quarter ending 06/30/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 14 | 8 | 8 | 14 | 12 |
| Average Estimate | 0.509 USD | -1.426 USD | -1.651 USD | -5.690 USD | -4.306 USD |
| Year Ago | -2.350 USD | -1.880 USD | -2.660 USD | - | -5.690 USD |
| Publish Date | 2/20/2024 | 4/30/2024 | 8/1/2024 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 12 | 8 | 8 | 14 | 13 |
| Average Estimate | 318 USD | 166 USD | 154 USD | 656 USD | 650 USD |
| Year Ago | 167 USD | 220 USD | 214 USD | - | 656 USD |
| Publish Date | 2/20/2024 | 4/30/2024 | 8/1/2024 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
*Yield of the Respective Date
PTC Therapeutics, Inc. is a biopharmaceutical company. It engages in discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Risk- Low
- Medium
- High
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
| Owner | in % |
|---|---|
| Freefloat | 96.49 |
| Wellington Management Co. LLP | 12.50 |
| Vanguard Group, Inc. (Subfiler) | 10.28 |
| RTW Investments LP | 9.59 |
| The Vanguard Group, Inc. | 9.52 |
| Fidelity Management & Research Co. LLC | 8.52 |
| Armistice Capital LLC | 8.15 |
| Fidelity Management & Research Co. LLC | 7.53 |
| Camber Capital Management LP | 5.30 |
| Camber Capital Management LP | 4.51 |
| State Street Corp. | 4.20 |
| Janus Henderson Investors US LLC | 4.02 |
| SPDR S&P Biotech ETF | 4.02 |
| BlackRock Fund Advisors | 3.93 |
| Vanguard Health Care Fund | 3.64 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
